Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline.

Chen, Alice, Kenneth P Smith, Betsy A Whitfield, Paola C Zucchi, Todd M Lasco, Tiffany E Bias, James E Kirby, and Elizabeth B Hirsch. 2017. “Activity of Minocycline Against Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Enterobacteriaceae Clinical Isolates, With Comparison to Doxycycline and Tigecycline.”. Diagnostic Microbiology and Infectious Disease 88 (4): 365-67.

Abstract

We examined the in vitro activity of minocycline against 103 Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae isolates and found approximately half had susceptible (26%) or intermediate (26%) MICs. For a subset of 35 isolates, susceptibility was highest to tigecycline (71% FDA vs. 20% EUCAST) followed by minocycline (14%) and then doxycycline (6%).

Last updated on 08/16/2024
PubMed